Burzynski Research Institute, Inc. (BZYR) Fair Value 2026

BZYR · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.4 /10

32 fundamental signals · 0 models active

Value Trap Risk

SAFE (21/100)

Quick Summary — As of 2026-08-27, Burzynski Research Institute, Inc. (BZYR) trades at $0.01. QOC: 4.4/10. Value Trap Risk: 21/100 (SAFE). 0/13 models active.

Key Facts

Ticker
BZYR
Price
$0.01
Quality Score
4.4/10
Value Trap Risk
21/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Below-average Quality Score of 4.4/10 signals weak fundamentals

What Fair Value Does Each Model Give BZYR?

0 Intrinsic Value Models vs. Current Price ($0.01)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is Burzynski Research Institute, Inc. (BZYR) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Burzynski Research Institute, Inc. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About BZYR?

0 of 13 models are currently active for BZYR. See which stocks rank higher →

How Does BZYR Rank in Biotechnology?

Among 620 Biotechnology stocks, BZYR ranks #466 by Quality of Company score. CirclFi's QOC score of 4.4/10 evaluates 32 fundamental signals. A score of 4.4 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

Within the Biotechnology space, Burzynski Research Institute, Inc. competes in an environment where partnership revenue often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.

Is BZYR a Value Trap?

CirclFi's Value Trap algorithm assigns BZYR a score of 21/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Burzynski Research Institute, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Burzynski Research Institute, Inc. is rated at 4.4/10. This moderate-tier score shows mixed signals across our quality framework with notable weaknesses.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every BZYR valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Burzynski Research Institute, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

10 related Biotechnology stocks with 13-model coverage

VERUVeru Inc.QOC 4.4ERNAErnexa Therapeutics Inc.QOC 4.4ONCYOncolytics Biotech Inc.QOC 4.4NWBONorthwest Biotherapeutics, Inc.QOC 4.4SGMTSagimet Biosciences Inc.QOC 4.4PTHSPelthos Therapeutics Inc.QOC 4.4EXELExelixis, Inc.QOC 9.6SLNSilence Therapeutics plcQOC 5.9CRVOCervoMed Inc.QOC 5.0INCYIncyte CorporationQOC 9.5

Read investment analysis: VERU · ERNA · ONCY · NWBO · SGMT · PTHS · EXEL · SLN · CRVO · INCY

Which Other Stocks Have a Similar Quality Score to BZYR?

6 companies across all industries closest to BZYR’s Quality of Company score of 4.4/10.

NCPLNetcapital Inc.QOC 4.4SVMBJingbo Technology, Inc.QOC 4.4BGLBlue Gold LimitedQOC 4.4MODDModular Medical, Inc.QOC 4.4NRISNorris Industries, Inc.QOC 4.4NVDANVIDIA CorporationQOC 10.0

Read investment analysis: NCPL · SVMB · BGL · MODD · NRIS · NVDA

Where Does BZYR Sit in CirclFi's Biotechnology Rankings?

BZYR is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Burzynski Research Institute, Inc.’s Valuation?

What is Burzynski Research Institute, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Burzynski Research Institute, Inc. (BZYR). The Quality of Company score is 4.4/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is BZYR overvalued or undervalued right now?

At $0.01, 0 of 0 active models suggest BZYR may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Burzynski Research Institute, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 4.4 mean for BZYR?

Burzynski Research Institute, Inc.'s QOC of 4.4/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on BZYR?

CirclFi analyzes BZYR with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is BZYR a value trap in 2026?

Burzynski Research Institute, Inc.'s Value Trap score is 21/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Burzynski Research Institute, Inc. (BZYR) a Quality of Company score of 4.4/10 across 32 fundamental signals as of 2026-08-27.” Source: circlfi.com/stock/BZYR/ · Methodology
Primary sources for this BZYR valuation
  • Financial statements: Burzynski Research Institute, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0000724445) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for BZYR as of ; valuations recomputed .